Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Mar 24:2019:9401628.
doi: 10.1155/2019/9401628. eCollection 2019.

Serum Vascular Endothelial Growth Factor Levels Correlate with Severity of Retinopathy in Diabetic Patients: A Systematic Review and Meta-Analysis

Zhongwei Zhou  1 , Huixiang Ju  1 , Mingzhong Sun  1 , Hongmei Chen  1
Affiliations
Meta-Analysis

Serum Vascular Endothelial Growth Factor Levels Correlate with Severity of Retinopathy in Diabetic Patients: A Systematic Review and Meta-Analysis

Zhongwei Zhou et al. Dis Markers. .

Abstract

Background: Investigations regarding serum and plasma vascular endothelial growth factor (VEGF) levels in patients with diabetic retinopathy (DR) are conflicting. This meta-analysis is aimed at determining whether serum and plasma VEGF levels are associated with DR and its severity in diabetic patients.

Methods: PubMed and EMBASE were used to search for published studies, and serum and plasma VEGF levels were compared among DR, nonproliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), and nondiabetic retinopathy (NDR) patients. Standardized mean differences (SMD) and 95% confidence interval (CI) were pooled using a random effects model.

Results: A total of 29 studies comprising 1805 DR (or NPDR or PDR) patients and 1699 NDR patients were included. ELISA was used to evaluate serum or plasma VEGF levels in all except for two studies included in this meta-analysis. Overall, serum VEGF levels were significantly higher in DR patients (SMD: 0.74, 95% CI: 0.44-1.03) than those in NDR patients, while plasma VEGF levels were not in the comparison (SMD: 0.40, 95% CI: -0.13-0.92). Similarly, NPDR (SMD: 0.51, 95% CI: 0.22-0.80) and PDR (SMD: 1.32, 95% CI: 0.79-1.85) patients had higher serum VEGF levels compared with NDR patients, but the difference was not significant in plasma samples (SMD: 0.24, 95% CI: -0.47-0.95; SMD: 0.37, 95% CI: -0.30-1.05). In addition, serum VEGF levels were higher in PDR patients than those in NPDR patients (SMD: 0.87, 95% CI: 0.41-1.33), but plasma VEGF levels were not (SMD: -0.00, 95% CI: -0.31-0.31). The subgroup and metaregression analysis revealed that the study location, study design, and publication year of a study have certain influence on heterogeneity between studies in serum or plasma samples.

Conclusions: VEGF levels in the serum instead of those in the plasma correlate to the presence and severity of DR in diabetic patients. Further large-scale studies are required to confirm these findings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the study selection process.
Figure 2
Figure 2
Forest plot summarizing the relationship of serum and plasma VEGF level in DR patients with those in NDR patients: serum (a) and plasma (b).
Figure 3
Figure 3
Forest plot summarizing the relationship of serum and plasma VEGF level in NPDR patients with those in NDR patients: serum (a) and plasma (b).
Figure 4
Figure 4
Forest plot summarizing the relationship of serum and plasma VEGF level in PDR patients with those in NDR patients: serum (a) and plasma (b).
Figure 5
Figure 5
Forest plot summarizing the relationship of serum and plasma VEGF level in PDR patients with those in NPDR patients: serum (a) and plasma (b).
Figure 6
Figure 6
Metaregression analysis of the relationship between the publication year and the effect sizes in serum and plasma samples: serum (a) and plasma (b).
Figure 7
Figure 7
Sensitivity analysis of included studies: serum (a) and plasma (b).
Figure 8
Figure 8
Visual inspection of funnel plots evaluating potential publication bias of included studies: serum (a) and plasma (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stitt A. W., Curtis T. M., Chen M., et al. The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research. 2016;51:156–186. doi: 10.1016/j.preteyeres.2015.08.001. - DOI - PubMed
    1. Wu H., Wu H., Shi L., et al. The association of haptoglobin gene variants and retinopathy in type 2 diabetic patients: a meta-analysis. Journal of Diabetes Research. 2017;2017:10. doi: 10.1155/2017/2195059.2195059 - DOI - PMC - PubMed
    1. Grigsby J., Betts B., Vidro-Kotchan E., Culbert R., Tsin A. A possible role of acrolein in diabetic retinopathy: involvement of a VEGF/TGFβ signaling pathway of the retinal pigment epithelium in hyperglycemia. Current Eye Research. 2012;37(11):1045–1053. doi: 10.3109/02713683.2012.713152. - DOI - PMC - PubMed
    1. Le Y. Z. VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases. Vision Research. 2017;139:108–114. doi: 10.1016/j.visres.2017.05.005. - DOI - PMC - PubMed
    1. Giocanti-Auregan A., Vacca O., Bénard R., et al. Altered astrocyte morphology and vascular development in dystrophin-Dp71-null mice. Glia. 2016;64(5):716–729. doi: 10.1002/glia.22956. - DOI - PubMed

Substances